Craig Eagle, M.D., serves as the Chief Medical Officer at Guardant Health Inc., a leading precision oncology company focused on developing blood tests for early cancer detection and monitoring. Dr. Eagle brings a wealth of experience in oncology, having spent over two decades in the field. Before joining Guardant Health, he held significant leadership roles at major pharmaceutical companies, including Merck and Bristol-Myers Squibb, where he was instrumental in advancing oncology drug development and clinical research. At Guardant Health, Dr. Eagle oversees the clinical and medical affairs teams, guiding the company's efforts to validate and expand its portfolio of liquid biopsy tests. His leadership has been pivotal in the successful development and commercialization of Guardant360, a groundbreaking test that analyzes circulating tumor DNA to help guide cancer treatment decisions. Under his guidance, Guardant Health has also made significant strides in early cancer detection, with the launch of the Shield test, aimed at detecting colorectal cancer in average-risk individuals. Dr. Eagle's contributions to the field of oncology extend beyond his corporate roles. He is a respected member of the medical community, frequently contributing to peer-reviewed journals and speaking at international conferences. His work at Guardant Health not only advances the company's mission but also plays a crucial role in the broader effort to improve cancer outcomes through innovative diagnostics.